Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Novo Nordisk · Phase 3 · Withdrawn · Enrollment 0

NCT07357766

ArmPopulationDoseWeeksEstimandWeight change
CagriSema B in device 2 + Placebo in device 1Obesity or overweightn/r16n/rn/r
CagriSema in device 1 + Placebo in device 2Obesity or overweightn/r16n/rn/r
Placebo in device 1 + Placebo in device 2Obesity or overweightn/r16n/rn/r